In attempting to seize the biotech Genzyme, Sanofi-Aventis hopes to enter a segment long ignored by major pharmaceutical companies, one of rare diseases.
It would appear that the giants of the industry think that investing in this field can be a good way to increase margins, complete the range of products and at least partially offset the impact of competition from generic.
Pfizer and GlaxoSmithKline have already tried the adventure but the offer from Sanofi on Genzyme – which could turn around 14.3 billion euros – would be by far the most advanced.
Genzyme is the world leader in treatments for rare diseases.He realized in 2009 a turnover of around 4.5 billion dollars from drug dealing rare inherited disorders such as Gaucher and Fabry disease.
"Genzyme has demonstrated to all that the market for rare diseases can be quite profitable," said Gary Pisano, a professor at Harvard Business School and a specialist in biotechnology.
These drugs for rare diseases, so-called "orphan" can reach astronomical prices and yet are rarely rejected by insurance companies.Cerezyme, blockbuster treating Gaucher disease developed by Genzyme, is an annual treatment cost of over $ 200,000.
This is one of the drugs most expensive in the world and represented the last year a turnover of 1.2 billion dollars.
NEW PERSPECTIVES
They are new opportunities opening up for big pharmaceutical companies that are themselves, most often, little to offer in terms of experimental medicines.
"The era of 'blockbuster' seems gone," says Kevin Gorman (Putnam Associates). "In rare diseases needs to look far the greatest."
Gaucher disease and Fabry disease are characterized by an enzyme deficiency that can cause irreparable damage or even lethal to the organs.Treating such diseases is not accessible to all laboratories and even the big pharmaceutical companies are not equipped to start from scratch in this field.
Design in this field of rare diseases, clinical trials, control of complex manufacturing processes and finally market drugs in highly targeted markets, this requires a special skill mastery that Genzyme to perfection.
Yet, one case of infection occurred at the site last year Genzyme Allston Landing in Boston, led to a shortage of two key drugs and led to a sharp drop in results and a diving action.
Sanofi hopes to capitalize on woes Genzyme to buy cheap.It offers 69 dollars per share, according to sources familiar with the matter, much less than the $ 80 where work is changing before disorders occur manufacturing end of 2008.
According to sources, it is unlikely that Genzyme accepts less than 80 dollars per share. This can be explained by the fact that Genzyme is an asset as rare as the diseases it treats.
It is not likely to be subject to generic competition soon.It has also more than 20 years of experience in the relationship with patient groups in the organization of clinical trials and reimbursement management and regulatory issues.
NOT EASY TO COPY
"The reasons why large groups are eyeing this segment reduced threat of generic products, products that can be expanded to other areas and prices," said Dominic Valder, an analyst at Evolution Securities.
Traditionally, the big pharmaceutical companies focus on drugs prescribed by GPs in a large population of patients with chronic conditions like diabetes, depression, ulcers or cholesterol is too high.
These medicines are made from molecules that can easily replicate génériquiers.
The biotech drugs are on the contrary from protein complex. They are prescribed by specialists for patients in small numbers. They are not easy to copy.
Some heavyweights pharmacy try their luck but so timidly.For Patrick Vallance, head of research at Glaxo, the strategy aims to improve the returns to research and development focusing on areas where the probability of success are greatest.
Glaxo has taken a stake in the Japanese and JCR Pharmaceuticals has entered into an alliance with privately held Prosensa, leading to the launch of a Phase III clinical trial in the second half and bearing on Duchenne muscular dystrophy.
Pfizer has acquired worldwide rights to an experimental treatment for Gaucher disease developed by Protalix BioTherapeutics, which if approved, would compete with Genzyme's Cerezyme.